Nervgen Pharma Corp Stock Price, News & Analysis

NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 545,000 incentive stock options to employees and consultants. The options include:

• 100,000 options to company officers
• 15,000 options to investor relations consultants
• Exercise price set at $2.74 per share

The options are structured in two categories: 15,000 options with a five-year term vesting quarterly over one year, and 530,000 options with a ten-year term vesting semi-annually over two years. All grants comply with TSX Venture Exchange policies and the company's stock option plan.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its upcoming presentation at the Virtual Life Sciences Investor Forum.

The company's President & CEO, Mike Kelly, will present on Thursday, March 13, 2025, at 12:00 p.m. EDT. The management team will be available for one-on-one virtual investor meetings during March 13-14 and March 17-18, 2025.

Individual and institutional investors, advisors, and analysts can pre-register for this interactive online event at VirtualInvestorConferences.com. For those unable to attend live, an archived webcast will be available on NervGen's website after the event.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 627,200 incentive stock options. The options were distributed to company employees, with 505,200 options allocated to Officers. These options are exercisable at $2.97 per share with a 10-year duration and vest equally every six months over a two-year period. The grants comply with TSX Venture Exchange policies and the company's stock option plan.

NervGen Pharma has announced the dosing of its first subject in the subacute cohort of its Phase 1b/2a clinical trial for NVG-291, targeting spinal cord injury (SCI) treatment. The trial (NCT05965700) is designed as a proof-of-concept, double-blind, randomized placebo-controlled study.

The company has implemented protocol amendments for the subacute cohort, including revising the timing window to 20-90 days post-injury and reducing the number of visits and assessments to decrease participant burden. The trial evaluates efficacy in two separate cohorts: chronic and subacute cervical spinal cord injury.

Results for the chronic cohort, which has completed enrollment, are expected in Q2 2025. The company plans to continue enrollment in the subacute cohort throughout 2025.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President & CEO, Mike Kelly, will engage in a fireside chat on February 11, 2025, at 8:40 a.m. EST.

The conference, scheduled for February 11-12, 2025, will be held in a virtual format. NervGen's management team will be available for one-on-one virtual meetings with investors throughout the conference. A webcast of the presentation will be made available and archived for later viewing.

NervGen Pharma has completed enrollment of 20 subjects in the chronic cohort of its Phase 1b/2a clinical trial for NVG-291, its lead candidate for spinal cord injury (SCI) treatment. The company expects to release topline data in Q2 2025 after completing data collection, review, database lock, unblinding, and analysis.

The company has also received IRB approval for a protocol amendment and begun screening subjects for the subacute cohort. The trial (NCT05965700) is designed as a proof-of-concept, double-blind, randomized placebo-controlled study.

Management believes their experience from recruiting the chronic cohort, combined with the recently approved protocol amendment, will improve the recruitment process for the subacute cohort while reducing the burden on participants.

NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF) has established an at-the-market equity program (ATM Program) allowing the company to issue and sell common shares through Stifel Nicolaus Canada Inc. The program has a limit of up to C$30 million in common shares, with sales occurring at prevailing market prices on the TSX Venture Exchange or other recognized marketplaces in Canada.

The ATM Program will run until December 19, 2026, unless terminated earlier. The company plans to use the net proceeds for general corporate purposes, including ongoing operations, working capital, research and development, intellectual property development, preclinical and clinical expenses, and potential future acquisitions. The program provides NervGen with enhanced flexibility for future additional financing needs.

NervGen Pharma reported Q3 2024 financial results, highlighting the approaching completion of target enrollment in the chronic cohort of their Phase 1b/2a clinical trial for NVG-291 in spinal cord injury. The company initiated preclinical studies for NVG-300 in ischemic stroke, ALS, and SCI. Financial results show cash position of $21.0 million as of September 30, 2024, with Q3 R&D expenses of $4.4 million and G&A expenses of $2.8 million. Net loss for Q3 was $5.2 million ($0.07 per share).

NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focusing on neurorestorative therapeutics, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Mike Kelly will lead a fireside chat on November 18, 2024, at 10:20 a.m. EST. The conference will be held at the Lotte New York Palace Hotel from November 18-19, 2024. Management will be available for one-on-one investor meetings during the event, and a webcast of the presentation will be available for replay.